Bei Akademie registrieren
Grifols, ES0171996087

Grifols stock pre-market at EUR 10.14: plasma therapies group trades

Published on 10/26/2026 at 08:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The Spanish healthcare group develops and distributes plasma-derived therapies. At Lang & Schwarz the stock trades pre-market at EUR 10.14 on October 26, 2026.

Business model and market

  • Grifols develops, manufactures, and distributes plasma-derived therapeutic products.
  • Spain is Grifols' home market on October 26, 2026.
  • Grifols stock trades pre-market at EUR 10.14 at 8:16 a.m. CET at Lang & Schwarz on October 26, 2026.
Aquarellbild von Barcelona mit Hafen, Bergen und mediterranem Licht
Aquarellmalerei zeigt die Küstenstadt Barcelona als Sitz von Grifols S.A. ES0171996087 in weichen, warmen Farbtönen, Illustration mit AI erstellt.

Grifols develops, manufactures, and distributes therapeutic products, with a primary focus on treatments derived from human plasma. The stock trades pre-market at EUR 10.14 at 8:16 a.m. CET at Lang & Schwarz on October 26, 2026.

Ahead of the Xetra open

Lang & Schwarz shows a bid of EUR 10.07 and an ask of EUR 10.21, representing a 1.38 percent spread. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Grifols stock.

How Grifols makes money

Grifols earns revenue from plasma-derived medicines and other healthcare products sold across the healthcare market. Spain is the company's home market on October 26, 2026. Market context: Market report IBEX 35.

More news and analysis on Grifols stock

Disclaimer...
en | ES0171996087 | GRIFOLS | boerse | 70412701 | bgmi